Abstract

Inactivation of the tumor suppressor p53 resulting from the binding with a negative regulator HDM2 is among the predominant defects in human cancers. p53-mimicking peptides whose conformational and proteolytic stability is enhanced by an all-hydrocarbon staple are being recognized as promising anticancer agents for disrupting the p53-HDM2 binding and reactivating p53. Herein, we conduct a computational modeling and thermodynamic characterization of stapled p53/HDM2 complex via molecular docking, simulations, and binding free energy analysis. The binding thermodynamics analysis is done based on the end-point calculation of the effective binding energy-a sum of the direct peptide-protein interaction energy and the dehydration penalty-and on its decomposition into contributions from specific groups constituting the complex. This allows us to investigate how individual amino acids in the stapled p53 and HDM2 contribute to the binding affinity. We find that not only the epitope residues (F19, W23 and L26), but also the hydrocarbon linker of the stapled p53 impart significant contributions. Our computational approach will be useful in designing new stapled peptides in which the staple location is also optimized to improve the binding affinity.

Highlights

  • The p53 protein is a transcription factor regulating cell cycle and apoptosis in response to DNA damages and cellular stresses [1]

  • We find that the epitope residues (F3, W7 and L10; colored magenta) of the stapled peptides and the hydrophobic residues located at the HDM2 binding surface are the principal contributors to the binding affinity

  • We present a computational method for modeling and characterizing stapled peptides and illustrate its application to a stapled p53/HDM2 complex

Read more

Summary

Introduction

The p53 protein is a transcription factor regulating cell cycle and apoptosis in response to DNA damages and cellular stresses [1]. It plays a critical role for maintaining the genome integrity and preventing the development of tumor [2]. P53-mimicking peptides incorporating these epitope residues will serve as potential anticancer agents that reactivate p53 by driving it out from the interaction with HDM2.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call